Diabetic Foot Ulcer Wound Fluid Biomarker
糖尿病足溃疡伤口液生物标志物
基本信息
- 批准号:10396775
- 负责人:
- 金额:$ 48.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-25 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAdoptionAdultAlgorithmsAmericanAmino AcidsAmputationAncillary StudyAreaBioinformaticsBiological AssayBiological MarkersBiopsyBlindedCaringCenters for Disease Control and Prevention (U.S.)CharacteristicsChronicClinicalClinical ProtocolsCollectionComplexComplications of Diabetes MellitusCysteineCystineDataDiabetes MellitusDiabetic FootDiabetic Foot UlcerDirect CostsEnrollmentEnvironmentEquilibriumFailureGoalsGoldHomeHospitalizationHospitalsImpairmentInfectionInflammationInterventionLimb structureLiquid ChromatographyLiquid substanceLower ExtremityMalignant NeoplasmsMass Spectrum AnalysisMetabolicMetabolismMulti-site clinical studyNamesNational Institute of Diabetes and Digestive and Kidney DiseasesNitrogenOutcomeOxidation-ReductionOxidative StressOxidesOxygenPathogenesisPatientsPerformancePersonsPhasePlayPopulationPreparationProtein BiosynthesisProtocols documentationPunch BiopsyRefractoryReportingRestRunningSample SizeSamplingSiteSulfhydryl CompoundsTestingTimeTissuesTreatment ProtocolsUnited States National Institutes of HealthValidationWorkaggressive therapybasebiobankc-myc Genescare costscare providerschronic ulcerchronic woundclinical biomarkersclinical research sitedemographicsdiabetic patientexperiencehealingimprovedinterestlimb amputationlimb lossmetabolomicsmortalitynon-healing woundsopen woundoxidationpoint of carepredictive markerprogramsprospectiveresearch clinical testingresponseskin ulcerstandard of carestatisticstissue repairworking groupwoundwound carewound healing
项目摘要
The 2020 CDC national diabetes statistics report identified that 34.2 million Americans, or 10.5% of the
population had diabetes in 2018. It is estimated that over the course of their lifetime up to a third of these people
with diabetes will develop a diabetic foot ulcer (DFU). The five-year mortality and direct costs of care for people
with diabetic foot complications are comparable to cancer. Approximately 40-60% of nontraumatic lower limb
amputations worldwide are caused by diabetic complications, and 80% of these amputations follow DFU. In
patients with hard-to-heal DFUs, treatment with multiple therapies is often necessary to manage stubborn
wounds. The current DFU treatment algorithm uses failure to improve (>50% wound area reduction) after four
weeks of standard of care (SoC) therapy to make a clinical decision on changing the therapy. The lack of
objective early indicators of wound healing outcomes handicaps DFU care strategy. Biomarkers that predict non-
healing (i.e., refractory to SoC) would provide an objective basis for rationally adopting alternate treatment
regimen to wound care providers in a timely manner. This proposal rests on our premise that non-healing diabetic
wounds would suffer from metabolic impairments which in turn would be reflected by changes in metabolites
contained in wound fluids (WF). A metabolomics approach was used to screen 578 metabolites from 161 WF
from chronic wound patients. Of all these metabolites, ONE PARAMETER emerged as a robust predictor of non-
healing: low Cysteine (Cys)/Cystine (CysS). A prospective preliminary study on DFU patients (N=24) showed
that low Cys/CysS in WF predicts non-healing. A point-of-care microtiter-plate (standard hospital assay platform)
based test was used. Because the proposed work seeks to establish Cysteine Redox as a biomarker of non-
healing or Open wound, the study is named CREDO. The R61 preparatory phase is named 2CREDO (towards
CREDO), and the R33 phase is referred to as CREDO. Aim 1: Validate the use DFU wound fluid low Cys/CysS
ratio (<3.43 cut-off) as a primary biomarker to predict non-healing of DFU. Aim 2: Develop a complete clinical
protocol to validate the use of Cys/CysS ratio in wound fluids to predict the healing of adult DFU. Aim 3: Conduct
a multi-center clinical study of diabetic foot ulcer patients to perform detailed validation of wound fluid based
Cys/CysS ratio as a biomarker to predict diabetic foot ulcer healing. Aim 4: Initiate discussions with FDA to
establish Cys/CysS as a clinical biomarker to predict DFU healing. The proposed work will be conducted as
ancillary Study of the current NIDDK Diabetic Foot Consortium (DFC) who have approved feasibility of our
protocol.
CDC 2020年全国糖尿病统计报告指出,3420万美国人,即10.5%的美国人
2018年人口患有糖尿病。据估计,在他们的一生中,多达三分之一的人
患有糖尿病的人会发展成糖尿病足溃疡(DFU)。五年死亡率和人们护理的直接成本
糖尿病足的并发症与癌症相当。约40%-60%的非创伤性肢体
世界各地的截肢手术都是由糖尿病并发症引起的,其中80%的截肢手术是在DFU之后进行的。在……里面
患有难以治愈的DFU的患者,通常需要采用多种治疗方法来管理顽固
伤口。当前的DFU治疗算法使用四次失败后改善(>;50%伤口面积减少)
数周的标准护理(SOC)治疗,以做出改变治疗的临床决定。缺乏
目的创面愈合结果的早期指标阻碍了DFU的护理策略。生物标志物可以预测非
治愈(即SOC的难治性)将为合理采用替代治疗提供客观依据
及时向伤口护理人员提供养生方案。这项提议基于我们的前提,即无法治愈的糖尿病患者
伤口会遭受代谢损伤,而代谢损伤又会通过代谢产物的变化反映出来。
包含在伤口液(WF)中。使用代谢组学方法从161名WF中筛选出578种代谢物
来自慢性伤口患者。在所有这些代谢物中,有一个参数是非
愈合:低半胱氨酸(Cys)/半胱氨酸(CysS)。一项对24例DFU患者的前瞻性初步研究显示
WF中低的Cys/CysS预示着无法愈合。医疗点微量试板(标准医院化验平台)
采用基于实验的测试方法。因为拟议的工作旨在将半胱氨酸氧化还原确立为非
无论是愈合还是开放创伤,这项研究被命名为CREDO。R61准备阶段被命名为2CREDO(朝向
CREDO),R33阶段称为CREDO。目的1:验证DFU创面液低半胱氨酸/半胱氨酸的使用
Ratio(<;3.43截断值)作为预测DFU无法愈合的主要生物标志物。目标2:建立一个完整的临床
验证伤口液中Cys/CysS比率预测成人DFU愈合的方案。目标3:行为
一项对糖尿病足溃疡患者进行伤口液详细验证的多中心临床研究
Cys/CysS比值作为预测糖尿病足溃疡愈合的生物标志物。目标4:发起与FDA的讨论以
建立Cys/CysS作为预测DFU愈合的临床生物标志物。拟议的工作将按以下方式进行
目前NIDDK糖尿病足联盟(DFC)已批准我们的可行性的辅助研究
协议。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sashwati Roy其他文献
Sashwati Roy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sashwati Roy', 18)}}的其他基金
Tissue reprogramming in diabetic wound healing
糖尿病伤口愈合中的组织重编程
- 批准号:
10936105 - 财政年份:2023
- 资助金额:
$ 48.59万 - 项目类别:
Tissue reprogramming in diabetic wound healing
糖尿病伤口愈合中的组织重编程
- 批准号:
10224448 - 财政年份:2021
- 资助金额:
$ 48.59万 - 项目类别:
Tissue reprogramming in diabetic wound healing
糖尿病伤口愈合中的组织重编程
- 批准号:
10382439 - 财政年份:2021
- 资助金额:
$ 48.59万 - 项目类别:
Mechanisms Underlying Impaired Diabetic Wound Healing
糖尿病伤口愈合受损的机制
- 批准号:
10205045 - 财政年份:2018
- 资助金额:
$ 48.59万 - 项目类别:
ZEISS PALM MicroBeam IV module Rel 4.2
ZEISS PALM MicroBeam IV 模块 Rel 4.2
- 批准号:
8052425 - 财政年份:2011
- 资助金额:
$ 48.59万 - 项目类别:
Mechanisms underlying impaired diabetic wound healing
糖尿病伤口愈合受损的机制
- 批准号:
8004785 - 财政年份:2009
- 资助金额:
$ 48.59万 - 项目类别:
Mechanisms underlying impaired diabetic wound healing
糖尿病伤口愈合受损的机制
- 批准号:
7580899 - 财政年份:2008
- 资助金额:
$ 48.59万 - 项目类别:
Mechanisms underlying impaired diabetic wound healing
糖尿病伤口愈合受损的机制
- 批准号:
8019532 - 财政年份:2008
- 资助金额:
$ 48.59万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 48.59万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 48.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 48.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 48.59万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 48.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 48.59万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 48.59万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 48.59万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 48.59万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 48.59万 - 项目类别:
Standard Grant














{{item.name}}会员




